In breast cancer, previous studies have confirmed that in patients with early stage triple‐negative and HER2‐positive disease, high levels of lymphocytic infiltration were consistently associated with a better prognosis, and these infiltrations reflect a good host anti‐tumor immune response, suggesting potential benefit of immune activation to improve prognosis.4 Here, ERBB2 is linked to breast cancer.